Ubrogepant

Ubrogepant is a prescription tablet used to treat a migraine attack after it has already started. It belongs to a newer drug class called calcitonin gene-related peptide receptor antagonists, usually shortened to CGRP receptor antagonists or gepants. United States labeling approves it for the acute treatment of migraine with or without aura in adults. It is not a preventive medicine.

This page explains what the official labeling says in everyday language, what side effects and interactions matter most, how the drug sits alongside other acute migraine treatment options, and what actually drives the monthly cost when you are paying yourself.

What ubrogepant is, in plain English

The brand name is Ubrelvy, marketed in the US by Allergan. It is a human prescription drug taken by mouth, so there is no over-the-counter version and no injection form. If you have seen it written out and wondered about pronunciation, clinical references write it roughly as ue-BROE-je-pant.

It is what clinicians call an abortive or acute treatment. You take it when an attack begins, not on a daily schedule. That is the single most important distinction on this page, because CGRP medicines come in both flavours: some are designed to stop an attack in progress, and others are designed to reduce how many attacks you get. This one is in the first group, and the label states plainly that it is not indicated for preventive treatment.

Who tends to be prescribed it? Broadly, adults with migraine who need something for attacks and either cannot use triptans, have not responded well to them, or cannot tolerate them. Because gepants do not narrow blood vessels the way triptans do, clinicians often consider them for people with cardiovascular risk factors that rule triptans out, as a published review of the drug’s mechanism and safety describes. It can also be used alongside a separate preventive plan, which is a conversation for your prescriber.

One more framing point: this is a headache-specific medicine, not a general painkiller. It has not been established for cluster headache or for other headache types, so a diagnosis matters before treatment does. For a wider view of related prescriptions and how they are grouped, the Medication Guide Index is a reasonable starting point.

How the CGRP pathway fits into a migraine attack

Calcitonin gene-related peptide, or CGRP, is a small protein released by nerve endings around the head. During a migraine attack, CGRP levels rise. It widens blood vessels and amplifies pain signalling in the trigeminal system, the nerve network that carries sensation from your face and scalp.

A gepant works by blocking the receptor that CGRP docks into. If the receptor is occupied, the released CGRP cannot pass its message along as strongly. That is the whole ubrogepant mechanism of action in one sentence: it sits on the CGRP receptor and blunts the signal instead of squeezing blood vessels shut.

Why does that distinction matter to you as a patient? Triptans, the older mainstay for attacks, work partly by constricting blood vessels. That is why their labeling restricts use in people with coronary artery disease, prior stroke, uncontrolled high blood pressure and similar histories. Gepants do not rely on constriction, which changes the safety conversation. It does not make them risk-free, and this page covers their own warnings further down.

On effectiveness, the honest summary is that it helps some people meaningfully and does nothing for others. In the pivotal randomised trial published in the New England Journal of Medicine’s ubrogepant study, more participants taking the drug were pain-free at two hours than those taking placebo, but plenty of people in the treatment groups still had pain. Migraine medicine is trial and error, and “is this a good migraine medication” is a question that only your own attacks can answer.

What US labeling approves, and how often the tablet can be used

The approved use is narrow and specific: acute treatment of migraine attacks, with or without aura, in adults. Aura means the visual or sensory warning symptoms some people get before or during an attack, such as flickering lights or tingling. Both types are covered.

The tablets come in two strengths, 50 mg and 100 mg. Searches for what the 100 mg tablet is used for have a simple answer: the same single indication as the 50 mg tablet, just at a higher amount per dose. Which strength suits a person, whether a second dose within the same day is appropriate, and what the maximum amount in 24 hours is are all set out in the current prescribing information published on DailyMed. Follow that and your prescriber, not a web page.

People also ask why there is a monthly ceiling on use. The reason is evidence, not punishment: the labeling states that safety has not been established for treating more than eight migraine attacks in a 30-day period. That is a gap in the data, so the label draws a line there. If you are hitting that ceiling regularly, that is a signal worth raising, because frequent attacks usually point toward a preventive strategy rather than more acute doses.

Two more practical notes from the label. First, it can be taken with or without food. Second, it is not a rescue plan for every headache; overusing any acute headache medicine can make headaches more frequent over time, which is a well-recognised pattern in headache care.

Side effects: common, uncommon and long-term questions

The side effects reported most often in studies are mild and short-lived. Nausea, sleepiness or drowsiness, and dry mouth are the ones that come up repeatedly in trials and in patient references such as the Mayo Clinic overview of the oral tablet. Because drowsiness is on that list, it is worth knowing how a first dose affects you before you drive or operate machinery.

Serious reactions are uncommon but real. Hypersensitivity reactions, including anaphylaxis and shortness of breath, have been reported. The important wrinkle is timing: these reactions can appear within minutes, within hours, or even days after a dose. Swelling of the face, lips, tongue or throat, hives, or trouble breathing means stopping the drug and getting emergency help.

Labeling also flags two circulation-related effects. New high blood pressure, or worsening of blood pressure that was already high, can occur. So can new or worsening Raynaud’s phenomenon, where fingers or toes go pale, numb or painful in the cold as small vessels narrow. Neither is common, but both are reasons to check in rather than push through.

What about long-term side effects? Here the honest answer is that the long-term picture for gepants is still being filled in, because they are a younger class than triptans. The known concerns are the ones above, and early liver signals that were seen with an abandoned earlier gepant have not been borne out for this one in approved use. Ongoing use is still worth reviewing periodically with a clinician, especially blood pressure.

Pregnancy and breastfeeding sit in the “not enough data” category. There is no established human safety profile, so the decision belongs in a conversation with your own prescriber rather than a general guide.

Warnings, interactions and cautions worth flagging

This drug is processed heavily by a liver enzyme called CYP3A4. That single fact drives most of the interaction list, and it is the part people most often miss.

• Strong CYP3A4 inhibitors are contraindicated. Taking the tablet with strong inhibitors such as certain antifungals, some antibiotics and some HIV protease inhibitors is not permitted by the labeling published through the FDA’s Drugs@FDA labeling database, because blood levels rise sharply.
• Moderate inhibitors and some transporter inhibitors call for dose changes. The label specifies how, and it varies by drug, so the prescription needs to be written with your full medicine list in hand.
• Strong and moderate CYP3A4 inducers should be avoided. Drugs and supplements that speed the enzyme up, including St John’s wort and some seizure and tuberculosis medicines, can push levels down far enough that the dose stops working.
• Grapefruit is not neutral. Grapefruit and grapefruit juice inhibit the same enzyme, so patient references advise avoiding them around dosing.
• Kidney and liver impairment matter. Severe impairment in either organ changes the recommended amount, and use is generally avoided in end-stage kidney disease.

The takeaway is not to memorise the list. It is to make sure whoever writes the prescription sees every prescription, over-the-counter product and supplement you take, including anything from a different telehealth program. Interaction checks are only as good as the list they run against.

Since blood pressure is one of the labeled cautions, a home log is more useful to a clinician than a single reading taken in a waiting room.

How it compares with other acute migraine treatment options

Most comparison searches land on two questions: ubrogepant versus rimegepant, and gepants versus triptans. Here is the neutral shape of the field. Every product has its own labeling, and the differences below are about role rather than ranking.

Two gepants aimed at the same moment in an attack will feel similar on paper. In practice, the deciding factors are usually formulation preference, whether you also need a preventive indication, what your plan will pay for, and how your body responds. Nothing published supports declaring one universally better than the other.

Cost without insurance, and what moves the number

Brand-only medicines for episodic conditions are expensive at list price, and this is one of them. Two payment routes exist and they are worth keeping separate in your head. Cash pay means the self-pay amount you hand over with no plan involved. With insurance means the plan or membership fee side of the equation only, before your own copays and deductibles, which vary by plan and by state.

Because advertised figures move, this guide does not quote a dollar amount for a one-month supply. What is stable is the list of things that change it:

• Brand status. Whether a generic version of the molecule exists in the US at any given time is the biggest single lever. Current approval and generic status are searchable in the FDA’s own database rather than in marketing copy.
• Tablet count, not days of supply. Acute migraine drugs are dispensed as a number of tablets. Someone treating two attacks a month and someone treating six are buying very different quantities.
• Plan design. Prior authorization, step therapy through cheaper triptans first, and monthly quantity limits are all common for this category. Denials and appeals are part of the process for many people, not a sign something went wrong.
• Pharmacy choice. Self-pay prices for the identical product differ between pharmacies. Asking two or three for the cash price on the exact strength and quantity is unglamorous and often the highest-value phone call you make.
• Program fees. If you go through a telehealth service, the consultation or membership fee is separate from what the pharmacy charges. Read which one a quoted figure refers to before you compare anything.

For coverage rules and how prescription benefit design works generally, the policy research published by KFF on prescription drug coverage and costs is a useful non-commercial reference. No page, including this one, can tell you whether your specific plan covers a specific tablet; only your plan’s formulary and your pharmacy can.

If you are trying to budget for an ongoing acute prescription, annualising the monthly figure you have been quoted tends to be more revealing than the monthly number alone.

Other free tools for tracking health and cost numbers sit together on the Free Patient Calculators page, and cost-comparison walkthroughs live in the Sample Savings Report.

Prescribing through telehealth, plus what to ask

Migraine care translates reasonably well to a screen, because diagnosis leans on history rather than hands-on examination. That said, prescribing rules are set state by state, and telemedicine licensure means the clinician must be licensed where you are physically located, not where the company is based. Programs differ enormously in how they handle this category.

A typical path looks like this:

1. You complete an intake covering headache history, attack frequency, aura, what you have already tried, other conditions and a full medicine list.
2. A licensed clinician reviews it, usually with a video or messaging visit, and confirms whether migraine is the working diagnosis.
3. If a gepant is appropriate, a prescription goes to a retail or mail pharmacy, and you pay the pharmacy separately from any platform fee.
4. Follow-up checks whether attacks are responding, how many doses you are using per month, and whether blood pressure or side effects need attention.
5. If attack frequency is high, the conversation shifts toward prevention rather than more rescue doses.

What varies between programs is worth comparing before you sign up: whether they treat headache at all or only stock a narrow formulary, whether they can bill insurance or are cash-pay only, whether the visit is live or asynchronous, whether a headache-experienced clinician or a generalist reviews the case, how refills and quantity limits are handled, and whether they will co-manage a preventive medicine. You can browse programs by condition and state in the Telehealth Provider Directory, read patient-written reviews on individual program pages, and see the criteria behind the comparison tables on the Scoring Criteria Explained page. Wider analysis of how these programs price and operate sits in our Independent Editorial Coverage.

Questions that get useful answers in a first visit: Is a gepant the right class for my history, or should I try something cheaper first? What do I do if the first dose does not work? How many attacks a month am I treating, and does that number mean I should be on prevention? Which of my other medicines interacts with this one? What should I watch for with blood pressure? What is the total monthly cost, split between your fee and the pharmacy?

When to get urgent care

Some head pain is not migraine, and telehealth is the wrong door for it. Seek emergency care for a sudden severe headache that peaks within seconds, the worst headache of your life, headache with fever and a stiff neck, weakness or numbness on one side, trouble speaking, sudden vision loss, confusion, seizure, or any headache that follows a head injury. Patient guidance from the Mayo Clinic’s migraine symptom overview covers these warning signs in more detail. Also treat breathing difficulty, throat tightness or widespread hives after a dose as an emergency, given the hypersensitivity warning on the label.

Authoritative sources

• MedlinePlus patient drug information from the National Library of Medicine
• Cleveland Clinic’s plain-language page on the tablets
• NINDS background on migraine and its treatment

Educational content, not medical advice. Always consult a qualified clinician before starting, stopping or switching treatment.